The results presented in this study indicate that it will be necessary to check monocyte abundance, along with patient symptoms, ESR, CRP, fecal calprotectin, and endoscopy results, when deciding whether to discontinue biologics in patients with IBD. This evidence concerns the gene CRP and inflammatory bowel disease.